×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MAZE – maze therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MAZE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/31
07:30 am
maze
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
Medium
Report
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
2/27
06:21 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Low
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
2/26
06:22 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
2/25
10:32 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Guggenheim. They set a "buy" rating and a $19.00 price target on the stock.
2/25
08:00 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.
2/25
08:00 am
maze
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $28.00 price target on the stock.
Medium
Report
Maze Therapeutics, Inc. (NASDAQ: MAZE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $28.00 price target on the stock.
2/7
09:35 am
maze
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]
Low
Report
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease [Yahoo! Finance]
2/7
08:00 am
maze
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
High
Report
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
07:35 am
maze
Form 10-K Maze Therapeutics, Inc. For: Dec 31
Medium
Report
Form 10-K Maze Therapeutics, Inc. For: Dec 31
3/31
07:32 am
maze
Form 8-K Maze Therapeutics, Inc. For: Mar 31
Medium
Report
Form 8-K Maze Therapeutics, Inc. For: Mar 31
2/28
05:30 pm
maze
Form SEC STAFF LETTER Maze Therapeutics, Inc.
Medium
Report
Form SEC STAFF LETTER Maze Therapeutics, Inc.
2/28
05:28 pm
maze
Form SEC STAFF LETTER Maze Therapeutics, Inc.
Medium
Report
Form SEC STAFF LETTER Maze Therapeutics, Inc.
2/10
10:56 am
maze
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
Medium
Report
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Frazier Life Sciences Public Fund, L.P.
2/7
04:31 pm
maze
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Deep Track Capital, LP
Medium
Report
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Deep Track Capital, LP
2/7
04:01 pm
maze
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Foresite Capital Fund IV, L.P.
Medium
Report
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Foresite Capital Fund IV, L.P.
2/7
04:01 pm
maze
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Foresite Capital Fund IV, L.P.
Medium
Report
Form SCHEDULE 13G Maze Therapeutics, Inc. Filed by: Foresite Capital Fund IV, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: